欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是 分享到:

中国临床药理学与治疗学 ›› 2006, Vol. 11 ›› Issue (9): 1060-1064.

• 研究原著 • 上一篇    下一篇

高效液相色谱串联质谱法测人血浆中氯雷他定浓度及其药代动力学研究

袁桂艳, 郭瑞臣, 王本杰, 刘慧   

  1. 山东大学齐鲁医院临床药理研究所, 济南 250012 , 山东
  • 收稿日期:2006-01-12 接受日期:2006-03-06 出版日期:2006-09-26 发布日期:2020-11-05
  • 作者简介:YUAN Gui-yan , female, postgraduate , majoring in clinical pharmacokinetics. Tel:13589031342 E-mail:yuangui1981@yahoo.com.cn

Determination of loratadine in human plasma by LC-MS and its pharmacokinetic studies

YUAN Gui-yan, GUO Rui-chen, WANG Ben-jie, LIU Hui   

  1. Institute of Clinical Pharmacology , Qilu Hospital of Shandong University , Jinan 250012 , Shandong , China
  • Received:2006-01-12 Accepted:2006-03-06 Online:2006-09-26 Published:2020-11-05
  • Contact: GUO Rui-chen , male , tutor of doctor , majoring in clinical pharmacology.Tel:0531-82169636  E-mail:grc7636 @126.com

摘要: 目的 建立灵敏的氯雷他定血浓度测定方法,评价氯雷他定的药代动力学特点。方法 固定相ORBAX Eclipse XDB-C8(5 μm , 150 mm ×4.6 mm),HP1100LC-MSD 质谱检测器;流动相乙腈-0.1 %醋酸和0.2 %醋酸铵水溶液, 流速1.0 ml·min-1 。离子源:AP-ESI , 正离子模式, 雾化电压30 psi , 保护气10 L·min-1N2 , 毛细管电压4 000 V , 碎片电压为170 V 。SIM 离子采集方式, 采集离子(m/z)氯雷他定383.2(M+H), 内标罗哌卡因275.1(M +H)。结果 氯雷他定线性范围0.5 ~ 50 ng·ml-1 , 最低定量限为0.5 ng·ml-1 。氯雷他定片(T1)、胶囊(T2)、开瑞坦(R)主要药代动力学参数t1/2为13.52 ±1.35 ,13.14 ±0.98 , 14.00 ±1.25 h;Tmax为1.24 ±0.06 ,1.18 ±0.12 , 1.18 ±0.12 h;Cmax 为21.72 ±7.70 ,21.49 ±8.34 , 20.50 ±8.65 ng·ml-1;AUC0-48 为137.24 ±47.87 , 139.65 ±45.69 , 134.19 ±49.03ng·h·ml-1 , AUC0 -∞为146.61 ±51.03 , 148.04 ±48.10 , 143.70 ±52.08 ng·h·ml-1 。试验制剂氯雷他定片/胶囊相对生物利用度分别为(105.49 ±8.08)%和(102.90 ±10.02)%。结论 HPLC-MS 法测定氯雷他定血浓度实用、可行, 适用于常规治疗药物监测和氯雷他定药代动力学研究。试验制剂和参比制剂为生物等效制剂。

关键词: 氯雷他定片/胶囊, 液相色谱/质谱联用, 药代动力学, 生物等效性, 开瑞坦

Abstract: AIM: To establish an LC-MS method for determining the concentrations of loratadine (LOR)in human plasma and to evaluate its pharmacokinetic characteristics.METHODS: A ZORBAX Eclipse XDB-C8 (5μm , 150 mm ×4.6 mm)column was used , atmospheric pressure electronic spray ionization (AP-ESI) and ion mass spectrum (m/z)of 388.2 (M+H)+were selected to quantify LOR , and 275.1 (M +H)+for ropivacaine(internal standard , IS).RESULTS: The linear range of LOR standard curve was 0.5 -50 ng·ml-1 , and the determination limit was 0.5 ng·ml-1.The pharmacokinetic parameters of LOR after a single dose of 20 mg tablet(T1), capsule (T2)and reference (R)were as follows ,the half life (t1/2)13.52 ±1.35 , 13.14 ±0.98 and 14.00 ±1.25 h , the time to peak concentration (Tmax) 1.24 ±0.06 , 1.18 ±0.12 and 1.17 ±0.12 h , the peak concentration (Cmax)21.72 ±7.70 , 21.49 ±8.34 and 20.50 ±8.65 ng·ml-1 , the area under time-concentration curve (AUC0 -48 and AUC0 -∞)137.24 ±47.84 and 146.61 ±51.03 ng·ml-1·h , 139.65 ±45.69 and 148.04 ±48.10 ng·ml-1·h , 134.19 ±49.03 and 143.70 ±52.08 ng·ml-1·h , the relative bioavailability of LOR tablet and capsule were (105.49 ±8.08)% and(102.90 ±10.02)%, respectively.CONCLUSION: The LC-MS method for determining the concentration of LOR in human plasma is sensitive and accurate and can be used for LOR bioavailability and pharmacokinetic studies.LOR tests and reference are bioequivalent.

Key words: loratadine, LC-MS, pharmacokinetics, bioequivalence, Clarityne

中图分类号: